Education
About Us
Working with TipRanks
Follow Us
Miravant Medical Technologies (MRVT)
:MRVT
MRVT Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
MRVT FAQ
What was Miravant Medical Technologies’s price range in the past 12 months?
Miravant Medical Technologies lowest stock price was $0.01 and its highest was $0.01 in the past 12 months.
What is Miravant Medical Technologies’s market cap?
Miravant Medical Technologies’s market cap is $38.00.
When is Miravant Medical Technologies’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Miravant Medical Technologies’s earnings last quarter?
Currently, no data Available
Is Miravant Medical Technologies overvalued?
According to Wall Street analysts Miravant Medical Technologies’s price is currently Overvalued.
Does Miravant Medical Technologies pay dividends?
Miravant Medical Technologies does not currently pay dividends.
What is Miravant Medical Technologies’s EPS estimate?
Miravant Medical Technologies’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Miravant Medical Technologies have?
Miravant Medical Technologies has 37,857,000 shares outstanding.
What happened to Miravant Medical Technologies’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Miravant Medical Technologies?
Currently, no hedge funds are holding shares in MRVT
Company Description
Miravant Medical Technologies
Miravant Medical Technologies Inc. operates as a pharmaceutical research and development company. The company develops PhotoPoint, a photodynamic therapy that responds to light destroying cancerous cells; and manufactures light producing and light delivery devices. Its products include PHOTREX for the treatment of wet age-related macular degeneration or AMD; MV9411, a photoreactive drug for the treatment of plaque psoriasis; MV0633 for the treatment of atherosclerosis, atherosclerotic vulnerable plaque, and restenosis; MV2101 for the treatment of vascular access graft disease in hemodialysis patients; and MV6401 for the treatment of solid tumors. Miravant Medical Technologies Inc. was formerly known as PDT, Inc. and changed its name to Miravant Medical Technologies Inc. in September 1997. The company was founded in 1989 and is headquartered in Santa Barbara, California.
Applied DNA Sciences
―
Salarius Pharmaceuticals
―
Matinas BioPharma
―
Hepion Pharmaceuticals
―
Windtree Therapeutics
―